Sheila Rodgers - Concepedia

Author

Sheila Rodgers

University of Sheffield

Also Known As

S Rodgers, S. Rodgers, Sheila Rodgers

Publications

373

Citations

H-Index

Concepts

All Affiliations

University of Sheffield Weston Park Cancer Centre

About

Sheila Rodgers is an author at University of Sheffield specializing in medicine, tumor biology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	214
2	Cell Biology	2	2	92
3	Immunology	2	2	46
4	Natural Sciences	1	1	64
5	Molecular Biology	1	1	64

Sheila Rodgers

Publications

373

Citations

H-Index

Page 1

	Year	Citations
Gene Therapy with Autologous, Interleukin 2-Secreting Tumor Cells in Patients with Malignant Melanoma Kay Palmer, J. Moore, M. Everard, Human Gene Therapy	1999	80
A Mutant Allele of<i>MRE11</i>Found in Mismatch Repair-deficient Tumor Cells Suppresses the Cellular Response to DNA Replication Fork Stress in a Dominant Negative Manner Qin Wen, Jennifer Scorah, Geraldine Phear, Molecular Biology of the Cell Mutant AlleleGeneticsMolecular BiologyTumor BiologyDominant Negative Manner	2008	64
An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma A Vora, Sheila Rodgers, R D Start, British Journal of Cancer Immunohistochemical StudyMalignant DiseasePathologyNeck PathologyHead And Neck Cancer	1997	61
Infrequent expression of the MAGE gene family in uveal melanomas Kevin Mulcahy, Donata Rimoldi, Francis Brasseur, International Journal of Cancer	1996	51
MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue AM Gillespie, Sheila Rodgers, A. T. Wilson, British Journal of Cancer Tumoral PathologyMedicineHistopathologyPathologyGynecology	1998	43
Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants Catherine McIntyre, Karen Chapman, Steve Reeder, European Journal of Cancer CytokineMelanomaImmunologyCulture SupernatantsImmune Checkpoint Inhibitor	1992	28
Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin‐2 (rhIL‐2) therapy Sheila Rodgers, Robert C. Rees, Barry W. Hancock British Journal of Haematology	1994	28
Malignant melanoma and renal cell carcinoma: Immunological and haematological effects of recombinant human interleukin-2 Khizar Hayat, Sheila Rodgers, Lesley J. Bruce, European Journal of Cancer and Clinical Oncology Recombinant Human Interleukin-2Cancer ImmunosurveillanceMelanomaImmunologyPathology	1991	18

Page 1